JPH02500403A - 梅毒トレポネーマの４７‐キロダルトン抗原のクローニングおよびその発現 - Google Patents
梅毒トレポネーマの４７‐キロダルトン抗原のクローニングおよびその発現Info
- Publication number
- JPH02500403A JPH02500403A JP62505911A JP50591187A JPH02500403A JP H02500403 A JPH02500403 A JP H02500403A JP 62505911 A JP62505911 A JP 62505911A JP 50591187 A JP50591187 A JP 50591187A JP H02500403 A JPH02500403 A JP H02500403A
- Authority
- JP
- Japan
- Prior art keywords
- treponema pallidum
- immunogen
- pallidum
- dna
- kda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000589884 Treponema pallidum Species 0.000 title claims description 113
- 108091007433 antigens Proteins 0.000 title claims description 66
- 102000036639 antigens Human genes 0.000 title claims description 65
- 239000000427 antigen Substances 0.000 title claims description 64
- 238000010367 cloning Methods 0.000 title description 8
- 230000002163 immunogen Effects 0.000 claims description 97
- 108020004414 DNA Proteins 0.000 claims description 67
- 208000006379 syphilis Diseases 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 35
- 239000012634 fragment Substances 0.000 claims description 34
- 239000013612 plasmid Substances 0.000 claims description 34
- 208000015181 infectious disease Diseases 0.000 claims description 28
- 230000001717 pathogenic effect Effects 0.000 claims description 26
- 239000000523 sample Substances 0.000 claims description 25
- 244000005700 microbiome Species 0.000 claims description 24
- 230000000813 microbial effect Effects 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 241000588724 Escherichia coli Species 0.000 claims description 17
- 239000013598 vector Substances 0.000 claims description 17
- 241000589886 Treponema Species 0.000 claims description 15
- 238000009396 hybridization Methods 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 12
- 108091008146 restriction endonucleases Proteins 0.000 claims description 11
- 108020004511 Recombinant DNA Proteins 0.000 claims description 10
- 210000004408 hybridoma Anatomy 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 230000003053 immunization Effects 0.000 claims description 5
- 241001529936 Murinae Species 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 238000002649 immunization Methods 0.000 claims description 4
- 239000013600 plasmid vector Substances 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- 239000013060 biological fluid Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 230000001014 anti-treponemal effect Effects 0.000 claims description 2
- 230000007969 cellular immunity Effects 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 38
- 230000036039 immunity Effects 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 21
- 244000052769 pathogen Species 0.000 description 13
- 239000000499 gel Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 241000589910 Treponema phagedenis Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000003156 radioimmunoprecipitation Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 108010023244 Lactoperoxidase Proteins 0.000 description 3
- 102000045576 Lactoperoxidases Human genes 0.000 description 3
- 201000000860 Secondary syphilis Diseases 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229940057428 lactoperoxidase Drugs 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000565 sealant Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 241000212384 Bifora Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241001646716 Escherichia coli K-12 Species 0.000 description 2
- 101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000589892 Treponema denticola Species 0.000 description 2
- 241000984746 Treponema vincentii Species 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- XNCSCQSQSGDGES-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(O)=O XNCSCQSQSGDGES-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101710092702 47 kDa protein Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000589893 Brachyspira hyodysenteriae Species 0.000 description 1
- 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 108010076804 DNA Restriction Enzymes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000007900 DNA-DNA hybridization Methods 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000605314 Ehrlichia Species 0.000 description 1
- 206010053025 Endemic syphilis Diseases 0.000 description 1
- 244000307700 Fragaria vesca Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 101710164702 Major outer membrane protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 241000287462 Phalacrocorax carbo Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000025884 Treponema infectious disease Diseases 0.000 description 1
- 108010052236 Treponema pallidum 47-kDa immunogen Proteins 0.000 description 1
- 241000732551 Treponema refringens Species 0.000 description 1
- 208000035055 Treponemal Infections Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 101150024923 da gene Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004124 hock Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000009090 primary syphilis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000005582 sexual transmission Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US913,724 | 1986-09-30 | ||
| US06/913,724 US4868118A (en) | 1986-09-30 | 1986-09-30 | Cloning and expression of the 47-kilodalton antigen of treponema pallidum |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH02500403A true JPH02500403A (ja) | 1990-02-15 |
Family
ID=25433526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62505911A Pending JPH02500403A (ja) | 1986-09-30 | 1987-09-21 | 梅毒トレポネーマの４７‐キロダルトン抗原のクローニングおよびその発現 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4868118A (enExample) |
| EP (1) | EP0324774B1 (enExample) |
| JP (1) | JPH02500403A (enExample) |
| AT (1) | ATE141325T1 (enExample) |
| AU (1) | AU8021487A (enExample) |
| CA (1) | CA1336692C (enExample) |
| CH (1) | CH676606A5 (enExample) |
| DE (1) | DE3751870T2 (enExample) |
| DK (1) | DK293988A (enExample) |
| IL (1) | IL84006A (enExample) |
| WO (1) | WO1988002403A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681934A (en) * | 1986-09-30 | 1997-10-28 | Board Of Regents, The University Of Texas System | 47-kilodalton antigen of Treponema pallidum |
| US4956230A (en) * | 1987-04-13 | 1990-09-11 | Minnesota Mining And Manufacturing Company | Ink receptive transparency sheet |
| WO1990015132A2 (en) * | 1989-05-24 | 1990-12-13 | Syntro Corporation | Cloned treponema hyodysenteriae endoflagellar antigen |
| US5474900A (en) * | 1990-03-16 | 1995-12-12 | Sekisui Chemical Co., Ltd. | Process for preparing purified syphilis antigen from Treponema palljdum |
| FR2707168B1 (fr) * | 1993-07-08 | 1995-08-18 | Rhone Merieux | Vaccin contre la dysenterie hémorragique du porc et ensemble de vaccination y relatif. |
| RU2103362C1 (ru) * | 1995-07-14 | 1998-01-27 | Товарищество с ограниченной ответственностью Биотехнологическая компания "БИОСЕРВИС" | Набор для обнаружения антител к бледной спирохете treponema pallidum, рекомбинантный полипептидный антиген treponema pallidum 15 кда, рекомбинантный полипептидный антиген treponema pallidum 17 кда и рекомбинантный полипептидный антиген treponema pallidum tmp a |
| DE19536166C1 (de) * | 1995-09-29 | 1997-03-06 | Siegfried Dr Krell | Verfahren zur Bestimmung von Antikörpern gegen Treponema pallidum (Syphilis) |
| US6020128A (en) * | 1997-06-10 | 2000-02-01 | United States Of Ameria | DNA polymerase from Treponema pallidum |
| WO1999053099A1 (en) * | 1998-04-10 | 1999-10-21 | University Of Washington | Recombinant proteins of treponema pallidum and their use for a syphilis vaccine |
| US6667038B1 (en) * | 1999-04-21 | 2003-12-23 | Boston Medical Center Corp. | Prevention, diagnosis and treatment of lyme disease |
| CA2794710C (en) | 2010-03-31 | 2018-05-08 | Sekisui Medical Co., Ltd. | Reagent for assaying anti-treponema pallidum antibody |
| JP5911889B2 (ja) | 2011-01-13 | 2016-04-27 | オーソ−クリニカル・ダイアグノスティックス・インコーポレイテッドＯｒｔｈｏ−Ｃｌｉｎｉｃａｌ Ｄｉａｇｎｏｓｔｉｃｓ， Ｉｎｃ． | 梅毒トレポネーマトリプレット抗原 |
| CN112772552B (zh) * | 2020-12-31 | 2022-05-17 | 青岛胶南康大饲料有限公司 | 肉兔饲养方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE427516B (sv) * | 1981-11-10 | 1983-04-11 | Ericsson Telefon Ab L M | Sett och anordning for att korrigera distortion i en pa elektronisk veg upptecknad av bildelement lengs linjer uppbyggd bild |
| US4514498A (en) * | 1982-05-26 | 1985-04-30 | The Board Of Regents, The University Of Texas System | Hybrid cell lines producing monoclonal antibodies directed against Treponema |
| JPS59502131A (ja) * | 1982-11-12 | 1984-12-27 | ザ リ−ジエンツ オブ ユニバ−シテイ オブ カリフオルニア | 組換えｄｎａ誘導型梅毒トレポネ−マ抗原 |
-
1986
- 1986-09-30 US US06/913,724 patent/US4868118A/en not_active Expired - Lifetime
-
1987
- 1987-09-21 WO PCT/US1987/002403 patent/WO1988002403A1/en not_active Ceased
- 1987-09-21 EP EP87906542A patent/EP0324774B1/en not_active Expired - Lifetime
- 1987-09-21 AU AU80214/87A patent/AU8021487A/en not_active Abandoned
- 1987-09-21 DE DE3751870T patent/DE3751870T2/de not_active Expired - Lifetime
- 1987-09-21 JP JP62505911A patent/JPH02500403A/ja active Pending
- 1987-09-21 AT AT87906542T patent/ATE141325T1/de not_active IP Right Cessation
- 1987-09-21 CH CH2160/88A patent/CH676606A5/de not_active IP Right Cessation
- 1987-09-23 CA CA000547633A patent/CA1336692C/en not_active Expired - Lifetime
- 1987-09-27 IL IL84006A patent/IL84006A/xx not_active IP Right Cessation
-
1988
- 1988-05-30 DK DK293988A patent/DK293988A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US4868118A (en) | 1989-09-19 |
| EP0324774A1 (en) | 1989-07-26 |
| CA1336692C (en) | 1995-08-15 |
| AU8021487A (en) | 1988-04-21 |
| WO1988002403A1 (en) | 1988-04-07 |
| DK293988D0 (da) | 1988-05-30 |
| CH676606A5 (enExample) | 1991-02-15 |
| DK293988A (da) | 1988-07-14 |
| IL84006A0 (en) | 1988-02-29 |
| ATE141325T1 (de) | 1996-08-15 |
| IL84006A (en) | 1992-11-15 |
| EP0324774B1 (en) | 1996-08-14 |
| DE3751870D1 (de) | 1996-09-19 |
| DE3751870T2 (de) | 1997-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0462210B1 (en) | Vaccines for nontypable haemophilus influenzae | |
| AU666329B2 (en) | Methods and compositions relating to useful antigens of (moraxella catarrhalis) | |
| EP0540457A1 (en) | Improvements in Borrelia burgdorferi diagnosis and prophylaxis | |
| Oaks et al. | Antigenic and genetic relatedness of eight Rickettsia tsutsugamushi antigens | |
| Norgard et al. | Cloning and expression of the major 47-kilodalton surface immunogen of Treponema pallidum in Escherichia coli | |
| JPH02500403A (ja) | 梅毒トレポネーマの４７‐キロダルトン抗原のクローニングおよびその発現 | |
| Fehniger et al. | Purification and characterization of a cloned protease-resistant Treponema pallidum-specific antigen | |
| US5350842A (en) | DNAs encoding Treponema pallidum antigens | |
| US5369005A (en) | Method for mycoplasma detection in a biological sample | |
| KR19990087436A (ko) | 치주염의 진단 및 치료용 포르피로모나스 긴기발리스 항원 | |
| US6143872A (en) | Borrelia burdorferi Osp A and B proteins and immunogenic peptides | |
| Ma et al. | Indirect enzyme-linked immunosorbent assay for detection of antibody to a 110,000-molecular-weight hemolysin of Actinobacillus pleuropneumoniae | |
| CA2033042A1 (en) | Methods for diagnosis of tuberculosis | |
| US5399485A (en) | Methods and compositions for diagnosing cat scratch disease and bacillary angiomatosis caused by Rochalimaea henselae | |
| EP0409895B1 (en) | A pasteurella vaccine | |
| US5436000A (en) | Flagella-less borrelia | |
| US5281694A (en) | Methods and compositions for production of mycoplasmal adhesins | |
| CA2190359C (en) | Nucleic acids of rochalimaea henselae and rochalimaea quintana and methods and compositions for diagnosing rochalimaea henselae and rochalimaea quintana infection | |
| EP2530087B1 (en) | Sequences of brachyspira, immunogenic composition, methods for preparation and use thereof | |
| US20110064761A1 (en) | Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof | |
| Fisher et al. | Immunoblot reactivity of polyclonal and monoclonal antibodies with periplasmic flagellar proteins FlaA1 and FlaB of porcine Serpulina species | |
| AU2535699A (en) | Method for detecting intimin producing microorganisms | |
| EP0915977A1 (en) | B. burgdorferi polypeptides expressed in vivo | |
| AU659094B2 (en) | Cloning and expression of toxoplasma antigens and use of recombinant antigens | |
| WO1984001961A1 (en) | Recombinant dna derived antigens of treponema pallidum |